Neridronic Acid is an investigational drug.
There have been 4 clinical trials for Neridronic Acid.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 20th 2016.
The most common disease conditions in clinical trials are Complex Regional Pain Syndromes, Syndrome, and Reflex Sympathetic Dystrophy. The leading clinical trial sponsors are Grünenthal GmbH and [disabled in preview].
There is one US patent protecting this investigational drug and thirteen international patents.